Patient P-01388
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
92%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S17
- Day 82 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 82 CR-01 recommended — Clinician Review CR-01
- Day 83 Patient accepted — Started CR-01 in the companion
- Day 88 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory began diverging from predicted response on Day 82.
Primary contributors, last 14 days
- GI instability+25
- Treatment adherence-20
- Inflammatory activity+19
- Nutritional resilience-16
- Toxicity+12
What helped?
- Clinician Review CR-01Day 82Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
60%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 69 and rising
- WearableSleep 4.7 h, below personal baseline
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 62
- WearableHRV 27 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 88 bpm
- Wearable2,923 steps/day
- WearableShort sleep window
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 53
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.1 · butyrate capacity 48/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 31 ms
- Sleep
- 5.0 h
- Steps
- 3,147
- Resting HR
- 86 bpm
Daily log: GI score 69, nutritional resilience 36, adherence 67.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01835 | 51% | S17 | CR-01 | improved | 56 |
| P-01459 | 49% | S02 | — | — | 51 |
| P-01778 | 49% | S08 | — | — | 59 |
| P-01623 | 46% | S16 | — | — | 52 |
| P-01696 | 45% | S20 | CR-01 | improved | 59 |
| P-01362 | 43% | S20 | — | — | 60 |
| P-01469 | 43% | S19 | — | — | 58 |
| P-01514 | 43% | S11 | — | — | 63 |
| P-01371 | 42% | S06 | CR-01 | improved | 63 |
| P-01521 | 41% | S14 | — | — | 53 |
| P-01699 | 41% | S04 | GI-04 | improved | 69 |
| P-01715 | 41% | S05 | — | — | 56 |